| Verdú & Navarro, 1997 (6) | 36 female mice; sciatic crush | Morphological and functional reinnervation assessment | Sensory responses, sweat-gland response, CMAP; up to 100 days | Histological reinnervation preceded recovery of some functional responses; morphology and function did not fully coincide. | Animal crush model; no chronic-pain endpoint. |
| Valero-Cabré & Navarro, 2002 (7) | 59 rats; 8-mm sciatic nerve resection | Autograft and tube-repair strategies; four repair groups included 42 rats within the 59-animal study | CMAP and walking-track SFI; 90 days | Axonal misdirection varied by repair method and was associated with poorer functional recovery. | Severe experimental lesion; no pain endpoint. |
| Boivin et al., 2007 (8)b | 208 adult male mice and 178 adult male rats across multiple experiments; sciatic crush | TLR2/TLR4/MyD88 signaling disruption | Myelin clearance, regeneration, motor recovery | Disrupted TLR signaling impaired debris clearance and delayed regeneration and functional recovery. | Animal study; no direct chronic-pain outcome; reported totals span multiple experiments. |
| Barrette et al., 2008 (9)b | 452 adult female mice across multiple experiments; peripheral nerve injury | Myeloid-cell depletion/requirement for myeloid cells | Debris clearance, axon regeneration, functional recovery | Myeloid cells were required for efficient debris clearance and axonal regeneration. | Animal study; no direct pain endpoint; exact cohort sizes vary by experiment. |
| Orita et al., 2013 (10) | Mouse; Schwann-cell-specific LRP1 deletion | Genetic disruption of Schwann-cell LRP1 | Remak bundles, axon–glia organization, mechanical sensitivity | LRP1 disruption altered Remak bundle organization and was associated with mechanical hypersensitivity and impaired repair. | Animal model; not CPSP; n varied by assay. |
| Su et al., 2019 (11) | Mouse sciatic crush | Schwann-cell P2X4 overexpression/BDNF signaling | Remyelination, motor and sensory function; multiple assay time points | P2X4/BDNF signaling supported remyelination and functional recovery; sensory testing assessed recovery after crush. | Animal study; mechanical sensitivity is not equivalent to a chronic neuropathic-pain endpoint; n varied by assay. |
| Xie et al., 2017 (12) | Rat SNL and SNI models | Assessment/manipulation of active regeneration and target reinnervation | Spontaneous activity, histology, pain-related behavior | Regenerating axons with failed target reinnervation were associated with persistent pain-related behavior; blocking regeneration reduced behavior in tested models. | Animal-only evidence; model-specific; no direct CPSP evidence. |
| Ren et al., 2016 (13) | Adult rats; sciatic nerve crush | Behavioral and histological follow-up of reinnervated skin | Mechanical/thermal sensitivity and histology to 8 weeks | Pain-related sensory abnormalities persisted in reinnervated skin despite progressive reinnervation. | Animal-only; stimulus-evoked outcomes; completeness/accuracy of regeneration not fully established. |
| Oliveira et al., 2018 (14) | 30 male rats; forelimb amputation | Time-course histology of traumatic neuroma formation | Histology at days 3, 7, 28, 60, and 90; n = 6 at each time point | Axonal sprouts were present early; disorganized axonal growth and histological neuroma features appeared from day 28 and became more prominent over time. | No pain behavior or electrophysiology; histology cannot distinguish painful from asymptomatic neuroma. |
| Dumanian et al., 2019 (15) | 28 human amputees; 30 residual limbs | Randomized trial: TMR vs standard neuroma treatment | Residual-limb and phantom pain; 1-year outcomes | TMR showed a favorable longitudinal signal for phantom-limb pain; primary intention-to-treat comparisons were not uniformly statistically significant. | Clinical evidence is specific to postamputation pain; trial stopped below target enrollment; pain change does not prove a regeneration-mediated mechanism. |
| Woo et al., 2016 (16) | 16 patients; 17 residual limbs | Retrospective RPNI pilot/case series; 46 RPNIs constructed | Neuroma and phantom pain; telephone-interview follow-up mean 7.5 ± 3.4 months (range 3–15) | Reported reductions in neuroma-related and phantom pain after RPNI. | No control group; postamputation setting; no direct measurement proving regeneration-mediated analgesia. |
| Senger et al., 2023 (17) | 36 Fischer rats; painful tibial neuroma model | Two experiments: (1) neuroma in situ vs excision (n = 6/group); (2) neuroma in situ vs TMR vs RPNI (n = 8/group) | Pain-related behavior (thigh tap and von Frey) and neuromuscular-junction reinnervation | TMR and RPNI reduced pain scores versus untreated neuroma controls in the second experiment. | Animal neuroma model; two experiments had different group sizes; findings are specific to this model and do not establish efficacy for general CPSP. |
| Bucan et al., 2019 (18) | 12 Wistar rats; sciatic nerve crush; in-vitro Schwann-cell and DRG-neuron assays | Rat adipose-derived MSC exosomes injected locally proximal and distal to the crush site | Footprint/SFI weekly to 21 days; neurofilament immunohistochemistry at day 21; in-vitro proliferation and neurite assays | Exosomes increased Schwann-cell proliferation in vitro; in vivo regenerated neurofilament-positive fibers were approximately 40% higher and SFI recovery improved. The in-vitro neurite-length increase was not statistically significant. | No pain-related behavior, neuropathic-pain, or CPSP outcome was assessed; short-term preclinical nerve-repair evidence only. |
| Chen et al., 2019 (19) | Rat sciatic nerve transection with a 10-mm nerve gap | Human adipose-derived stem-cell exosomes delivered in Matrigel within a silicone conduit | Schwann-cell proliferation, migration and myelination; axonal regeneration; muscle atrophy recovery | Exosomes improved Schwann-cell function, axonal regeneration, myelination, and recovery of denervation-related muscle atrophy. | No pain-related behavior or CPSP outcome was assessed; preclinical nerve-repair evidence only. |
| Zhao et al., 2020 (20) | Rat sciatic nerve crush; four exosome-dose groups (n = 6 per dose group) | Intramuscular BMSC-derived exosomes on days 0, 7, and 14 | SFI and thermal paw-withdrawal latency through day 28; regenerated-fiber number and diameter; DRG gene expression | Exosomes improved nerve regeneration and functional recovery; the 0.9 × 10¹⁰ particles/ml dose showed favorable results in several measures, but no clear linear dose–response relationship was established. | Short-term preclinical study; thermal withdrawal was an evoked sensory measure, not evidence of analgesia; no persistent neuropathic-pain or CPSP outcome was assessed. |